Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT02681991

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02681991
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02681991. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01 (registry gives no type); primary completion 2016-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.
Condition
Chronic Renal Failure
Intervention (Drug)
Renamezin capsule
Lead sponsor
Daewon Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02681991
Content hash
b143fbed2e7174f47dc58e72bd3763f996407c5b5699827d3e57b6b9a897870a